8 years ago

Treos Bio Raises $8 Million for Colorectal Cancer Vaccine Clinical Trials

  • Treos Bio, a UK and US-based developer of precision cancer immunotherapies, has secured $8 million in funding

  • The company plans to use the funds to initiate early-stage human clinical trials of its PolyPEPI™ Immunotherapy Cancer Vaccine for colorectal cancer

  • Treos Bio has completed preclinical development of therapeutic vaccines for multiple cancer types and intends to target patients identified as likely responders using its companion diagnostics

  • The company expects to start a first-in-man trial in 2017.

      • ProblemHealthcare

      "Existing cancer treatments are often ineffective or have severe side effects. The current cancer treatments lack personalized precision which limits treatment success and makes it difficult to develop new therapies."

      Solution

      "Treos Bio is developing personalized cancer immunotherapies paired with companion diagnostics to effectively target and kill cancer cells while minimizing side effects for patients."

      Covered on